From: Langerhans Cell Histiocytosis Treatment (PDQ®)
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Table 2. Clinical Classification of LCHa
| Clinical Group | Description | ||
|---|---|---|---|
| Multisystem | Two or more systems involved | ||
| With risk-organ involvement | Involvement of liver, spleen, or bone marrow | ||
| Without risk-organ involvement | Without involvement of liver, spleen, or bone marrow | ||
| Single-system | Only one system involved | ||
| Single site | Skin, bone, lymph node, other (thyroid, thymus) | ||
| Multiple sites | Multifocal bone disease | ||
| Special site | Skull-base lesion with intracranial extension or vertebral lesion with intraspinal soft tissue extension | ||
| Pulmonary LCH | Isolated lung disease | ||
| CNS LCH | Tumorous lesions | ||
| Neurodegenerative disease | |||
| LACI | |||
| LACS | |||
CNS = central nervous system; LACI = LCH-associated abnormal CNS imaging; LACS = LCH-associated abnormal CNS symptoms; LCH = Langerhans cell histiocytosis.